Document is current
Any future updates will be listed below
-
Authors
Herman, Elton Jalis
Allione, Alessandra
Viberti, Clara
Manfredi, Marcello
Russo, Alessia
Sana-Hafeez, Khadija
Kaiser, Nina
Johnen, Georg
Brüning, Thomas
Mirabelli, Dario
Dianzani, Irma
Agudo, Antonio
Weiderpass, Elisabete
Simeon, Vittorio
Kaaks, Rudolf
Turzanski-Fortner, Renée
Tumino, Rosario
Milani, Lorenzo
Gálvez-Navas, José María
Schulze, Matthias B.
Schiborn, Catarina
Castro, Natalia Cabrera
Masala, Giovanna
Guevara, Marcela
Vineis, Paolo
Casalone, Elisabetta
Matullo, Giuseppe
-
Funding
Funding for this research was provided by:
Fondazione AIRC per la ricerca sul cancro ETS (D15D18000410001)
- License Information
-
More Information
Article History
Received: 6 November 2025
Accepted: 12 January 2026
First Online: 20 February 2026
Declarations
:
: The Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA) has supplied DLD Diagnostika GmbH with the antibodies to produce the Calretinin ELISA kits. In turn, the IPA has received Calretinin ELISA kits at a reduced price and may benefit from future sales of the kits. Otherwise, the individual authors declare no competing interests.
: The study was approved by the Institutional Review Board of IARC and the ethics committees in the participating countries. All participants gave their written informed consent to participate in the EPIC study. The present study was carried out in accordance with the ethical principles of the Declaration of Helsinki.
: Not applicable.
